Blogs FGF21 Signaling Explained: Metabolic Function, FGFR/β-Klotho Biology, and In Vitro Assay Tools

FGF21 Signaling Explained: Metabolic Function, FGFR/β-Klotho Biology, and In Vitro Assay Tools

FGF21: A Hormone-Like Growth Factor Bridging Metabolism and Receptor Signaling

Fibroblast Growth Factor 21 (FGF21) is an atypical member of the fibroblast growth factor family that has attracted significant interest due to its endocrine effects on metabolism. Unlike canonical FGFs, which typically function in a paracrine or autocrine manner to control cell proliferation, growth, and differentiation, FGF21 operates as a circulating hormone that orchestrates energy homeostasis, lipid metabolism, and adaptive responses to nutritional stress.1 This unique physiological role places FGF21 at the intersection of metabolic regulation and receptor signaling biology.

The FGF19 Subfamily: Endocrine FGFs with Systemic Impact

FGF21 belongs to the FGF19 subfamily, which also includes FGF19 and FGF23. Members of this subgroup share several key structural and functional features that distinguish them from other FGFs. Most notably, they lack a conventional heparin-binding domain, which allows them to diffuse freely through circulation rather than remaining sequestered in the extracellular matrix. In addition, these ligands require co-receptor proteins from the Klotho family, specifically β-Klotho (KLB) or α-Klotho, to confer receptor specificity and enable productive signaling.2,3

For FGF21, β-Klotho acts as an essential co-receptor that defines its tissue-specific activity. The distribution of β-Klotho across select organs such as the liver, adipose tissue, and central nervous system determines where FGF21 can signal, restricting its endocrine activity to metabolically relevant sites.

FGFR Interactions: β-Klotho as the Essential Partner

FGF21 alone exhibits minimal affinity for FGF receptors (FGFRs). Its signaling competency depends on forming a ternary complex with β-Klotho and specific “c-isoforms” of FGFRs—namely FGFR1c, FGFR2c, and FGFR3c.1 Among these, the FGFR1c/β-Klotho complex appears to be the principal signaling node mediating the hormone’s metabolic effects in adipose tissue and the central nervous system.4

Upon ligand binding, this receptor complex activates intracellular signaling cascades, most prominently the RAS-MAPK, PI3K/AKT, and PLCγ pathways, leading to transcriptional programs that enhance glucose uptake, lipid oxidation, and thermogenesis. FGFR2c and FGFR3c can also participate in signaling depending on tissue expression, while FGFR4 interacts only weakly and is not considered physiologically significant for FGF21’s effects.5 This selective receptor engagement underlies the hormone’s precise metabolic influence and has made FGFR–β-Klotho a target for therapeutic intervention.

Tissue-Specific Mechanisms of Action

FGF21 exerts effects across several organs, acting as a coordinator of metabolic adaptation. In the liver, FGF21 expression is primarily induced by hepatocytes under conditions of fasting, ketogenic diet, or activation of the nuclear receptor PPARα.6,7 Once secreted, hepatic FGF21 promotes fatty acid oxidation, ketogenesis, and gluconeogenesis.

In adipose tissue, FGF21 acts predominantly through the FGFR1c/β-Klotho complex to enhance glucose uptake and lipolysis, as well as to induce thermogenic genes such as UCP1 in brown and beige adipocytes.8 These actions increase energy expenditure and improve insulin sensitivity. Within the pancreas, FGF21 has been shown to promote insulin secretion and support β-cell survival during metabolic stress. In the central nervous system, FGF21 crosses the blood-brain barrier to influence feeding behavior, energy expenditure, and circadian rhythm regulation via hypothalamic FGFR1c/β-Klotho signaling.9, 10

Through this multi-organ coordination, FGF21 integrates metabolic information across tissues to maintain energy homeostasis, particularly under stress conditions such as fasting, cold exposure, or overnutrition.

Therapeutic Potential and Drug Development

Given its broad metabolic effects, FGF21 has emerged as a promising therapeutic candidate for metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Several engineered analogs and mimetics have been developed to enhance its pharmacokinetic stability and bioactivity.

Despite these advances, challenges remain in optimizing receptor selectivity, minimizing potential side effects, and extending therapeutic half-life. Ongoing research into the molecular mechanisms of FGFR/β-Klotho signaling continues to inform next-generation FGF21-based therapies and small-molecule agonists designed to recapitulate its beneficial metabolic effects.

In Vitro Models for Studying FGF21 Signaling

In vitro assay systems provide platforms for dissecting FGF21 receptor interactions and signaling dynamics. Reporter gene assays utilizing FGFR1c, FGFR2c, or FGFR3c can quantitatively assess functional activation using pathway-specific transcriptional response elements.

Such models are instrumental in screening FGF21 analogs, evaluating receptor-specific pharmacology, and identifying modulators of FGFR signaling. They also support translational research efforts aimed at linking receptor activation profiles to metabolic outcomes observed in vivo.

Conclusion

FGF21 functions not as a local growth factor, but as a systemic hormone that coordinates energy metabolism across multiple organs. Its dependence on β-Klotho for selective activation of FGFR1c, FGFR2c, and FGFR3c defines a unique mode of receptor specificity that underlies its metabolic effects. As the biological and therapeutic understanding of FGF21 continues to evolve, this ligand remains a focal point for both basic research and translational innovation in metabolic disease.

 

References

  1. Kharitonenkov, A., & Adams, A. C. (2013). Inventing new medicines: The FGF21 story. Molecular Metabolism, 3(3), 221–229.
  2. Goetz, R., et al. (2007). Molecular insights into the Klotho-dependent, endocrine mode of action of FGF19 subfamily members. Molecular Cell Biology, 27(9):3417-28.
  3. Kurosu, H., et al. (2006). Regulation of fibroblast growth factor-23 signaling by Klotho. The Journal of Biological Chemistry, 281(10), 6120–3.
  4. Adams, A. C., et al. (2012). FGF21 requires βKlotho to act in vivo. PLoS One, 7(11):e49977.
  5. Yie, J., et al. (2009). FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Letters, 583(1), 19–24.
  6. Badman, M. K., et al. (2007). Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketosis. Cell Metabolism, 5(6), 426–37.
  7. Inagaki, T., et al. (2007). Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metabolism, 5(6), 415–25.
  8. Fisher, F. M., et al. (2011). Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology, 152(8), 2996-3004.
  9. Bookout, A. L., et al. (2013). FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nature Medicine, 19, 1147–1152.
  10. Liang, Q., et al. (2014). FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes, 63(12), 4064–75.